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For  many  decades  the  only  adjuvants  accepted  in human  licensed  vaccines  have  been  particulate  sub-
stances  such  as alum  and  emulsions.  These  compounds  have  been  identiﬁed  empirically,  based  on  their
ability to enhance  immune  responses  to vaccination  in  animals,  without  understanding  their mecha-
nism  of  action.  Thanks  to the  increased  knowledge  of the innate  immune  system,  many  new  adjuvants,
designed  around  known  Pattern  Recognition  Receptors  (PRRs)  including  Toll-like  receptors  (TLRs)  have
been identiﬁed.  A TLR4  agonist  is  part  of  a  licensed  vaccine  and  TLR9  ligands  are  in late  stage  clinical
testing.  Adjuvants  targeting  alternative  PRRs  have  been  validated  in  preclinical  models.  In  the  future  we
have  to expect  more  sophisticated  adjuvant  formulations,  including  multiple  PPR  ligands  combined  with
novel  antigen  delivery  systems.  In addition  to traditional  adjuvants,  other  innovative  strategies  improv-
ing  vaccine  immunity  are  emerging.  Among  them  combinations  of vaccines  with  cytokines,  inhibitors  of
metabolic  pathways,  modulators  of  baseline  inﬂammation  levels,  monoclonal  antibodies  targeting  check-
point inhibitors  and compounds  depleting  of  regulatory  cells.  The  introduction  of  novel  technologies  has
the  potential  to support  the  development  of  vaccines  with  increased  efﬁcacy  targeting  infections  as  well
as non-communicable  diseases.  However,  the  full potential  of  any  novel  vaccine  strategy  can  be  only  cap-
tured  if vaccination  programs  are  implemented  with sufﬁcient  coverage.  New  methods  to  fully capture
the  beneﬁts  of vaccination  and  appropriate  communication  strategies  to increase  vaccine  acceptance  by
the public  are two key elements  that all stakeholders  involved  in  the whole  vaccine  development  cycle,
including  scientists,  must  consider  very  carefully.
©  2015  The  Author.  Published  by Elsevier  Ltd.  This  is an  open  access  article  under  the  CC  BY-NC-ND
license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).. Introduction
This special issue of Vaccine derives from a workshop called
Enhancing vaccine Immunity and Value” held in Siena, Italy, on
uly 2014, where scientists from academic and industrial sectors
et  with clinical trial investigators, epidemiologists, regulators,
ealth care professionals and economists. During this unique meet-
ng several contributors have addressed two related questions that
re generally discussed in separate forums and journals. The ﬁrst
uestion was: how can we  discover and develop vaccines that are
ore immunogenic and prevent or cure an increasing number of
arget diseases? The second, related question was: once we have
emonstrated that novel vaccines work, what is the best way  to
ully capture their value and ensure their implementation?Scientists generally focus on the ﬁrst question, with the assump-
ion that demonstrating that a novel vaccine is efﬁcacious and safe
ill inevitably trigger its universal implementation and acceptance
∗ Tel.: +39 0577245102.
E-mail address: ennio.de gregorio@novartis.com
ttp://dx.doi.org/10.1016/j.vaccine.2015.01.087
264-410X/© 2015 The Author. Published by Elsevier Ltd. This is an open access article unby the public. However this is not always the case and even the
best vaccine in the world is useless if not implemented with
sufﬁcient coverage of the appropriate target population. It is
important that the scientiﬁc world is fully aware of the potential
obstacles that may limit vaccine implementation and acceptance
because there is a lot that scientists can do during the devel-
opment cycle to prevent them. For example, vaccine excipients,
manufacturing process, number of doses, route of administration,
number of vials, reactogenicity proﬁle are all aspects that may
affect acceptance and must be taken into account during vaccine
development.
By contrast, economists and health care professionals that
are responsible for vaccine implementation and recommendation
sometime have a superﬁcial knowledge of the science behind vac-
cines, including their mechanism of action. This is particularly true
when innovative components such as adjuvants are added to the
formulation. Explaining what the adjuvants do can help addressing
public perception of risk. Scientists have the responsibility to com-
municate in a simpler way how vaccine adjuvants work to avoid
any public and professional concern as nicely reported in this issue
by David Salsbury [19].
der the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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The most important and unique aspect of this special issue,
hich reﬂects the spirit of the original Siena workshop, is to put
ogether all relevant stakeholders that are involved in vaccine dis-
overy and implementation and try to learn from each other.
. Vaccine adjuvants
A large part of this issue is dedicated to what can be done to
nhance vaccine immunogenicity and efﬁcacy with a special focus
n vaccine adjuvants. As highlighted by O’Hagan et al. [20], from
mpirical particulate adjuvants that have been developed with-
ut knowing their mechanism of action, the ﬁeld is now moving
oward rationally design adjuvants that are based on synthetic
ompounds targeting known cells and receptors. However, it must
e said that now we know more about the mechanism of action
f some empirical adjuvants and this knowledge can help design-
ng future effective adjuvants [1]. In addition, traditional adjuvants
uch as Alum and Emulsions have been used in human vaccines for
ecades and have a very well established safety proﬁle. The safety of
he oil-in-water emulsion MF59 has been addressed in great details
n this issue by Steven Black [21].
More recently a novel natural compound adjuvant called
onophosphoryl lipid A (MPL), targeting TLR4, has been introduced
n a licensed HPV preventive vaccine. Novel synthetic analogs
f MPL  are in development phase as already mentioned in this
ssue by Steven Reed [22]. As of today many additional adju-
ants targeting TLRs have been tested in human and some, such
s TLR9 agonists, are very close to be licensed. Therefore, in the
ear future human vaccines containing novel TLR agonist that
ddress speciﬁc needs tailored to the pathogens will be very likely
ntroduced.
There are common themes in the strategy adopted by the vari-
us research teams that are developing novel vaccines containing
LR agonists. One important issue, addressed by different lab-
ratories through alternative solutions, is how to link adjuvant
o vaccine antigens. Preclinical data in fact suggest that the co-
elivery of TLR agonists with vaccine antigens improve not only
he antigen speciﬁc adaptive responses, but also the safety pro-
le of the vaccine, by avoiding unwanted activation of immune
ells that do not present the vaccine antigens. Some laboratories
re exploring direct conjugation of the TLR agonist to the anti-
en using chemical linkers [2]. Other teams are using traditional
elivery systems such as alum or liposomes [3] or biodegradable
icroparticles [4]. Another common objective is to improve the
eactogenicity proﬁle of TLR agonists by limiting systemic expo-
ure. This objective can be achieved by designing TLR agonists
hat are not very soluble and therefore retained at the site of
njection, or by adsorbing soluble TLR agonists to particulate adju-
ants [5]. Finally, a signiﬁcant amount of work of various research
eams is dedicated to selecting the best combination of different
LR agonists in the same vaccine or in mixing TLR agonists with
ther adjuvants that target different PPR [4,6]. In this regard, it
s worth mentioning that a combination adjuvants called AS01,
ncluding liposomes, MPL  TLR4 agonist and QS21 saponin is a com-
onent of a novel vaccine based on a RTS,S recombinant antigen
hat demonstrated efﬁcacy in preventing malaria in Phase III trials
7]. A second combination adjuvant, called AS15, including both
LR4 and TLR9 agonists is in Phase III evaluation in a vaccine
ased on a recombinant tumor-associated antigen (MAGE-3) for
he therapy of non-small-cell lung cancer (NSCLC) and melanoma.
hase II studies have demonstrated that the MAGE-3/AS15 vac-
ine can improve the disease free interval in a subset of melanoma
atients [8].
TLRs are not the only innate immune receptors that can improve
daptive responses to vaccination. Other important PRR potential3S (2015) B60–B63 B61
targets for vaccine adjuvants are: C-type lectins expressed on criti-
cal dendritic cell subsets; cytoplasmic sensors of bacterial cell wall
component NOD1 and NOD2; cytoplasmic sensor of RNA such as
RIG-I and MDA5 and the cytoplasmic sensor of cyclic di-nucleotides
STING. A lot of work is in progress trying to identify synthetic ago-
nists for these receptors including small molecule adjuvants [9].
Another class of adjuvants that have been investigates by several
teams are CD1d binding glycolipids activators of invariant NKT cells
[10].
In summary the increased knowledge of innate immunity path-
ways has allowed for the discovery of several immunepotentiators
targeting alternative receptors. The most advanced adjuvants at
the moment trigger TLR signaling, however preclinical studies have
already demonstrated that other PRRs can be effectively targeted.
All these novel immunepotentiators can be used in isolation or in
combination to improve response to vaccination by increasing anti-
body titers and CD4T cell frequencies, by improving memory and
persistency of all adaptive responses and by modulating the qual-
ity of CD4T cells and antibody isotypes according to the infectious
disease that the needs to be prevented or the medical need in gen-
eral. What immunepotentiators have failed to do in human, despite
encouraging results in preclinical models, was to induce high fre-
quencies of CD8T cell when combined to subunit vaccines. Probably
for CD8 responses the best approach is to use viral or nucleic acid
vectors instead of relying on cross-presentation processes boosted
by adjuvants.
The introduction some of the novel adjuvants described above in
human vaccines largely depends on the ability to perform adequate
early clinical trials as reported here by Della Cioppa et al. [23]. The
early stages of clinical development are critical to address several
complex questions such as antigen dose; adjuvant dose and optimal
vaccine schedule through innovative factorial trial design. Early,
exploratory clinical trials are also important to address the impact
of adjuvants on (1) early local and systemic innate immune reac-
tions; (2) the kinetics of antibody and T cell responses; (3) long term
persistence of protective responses; and (4) quality of T cell and
antibodies. The implementation of a systems biology approaches
to human immunology can greatly help to elucidate the impact of
adjuvants on vaccine safety and efﬁcacy as demonstrated by sev-
eral recent studies on human vaccinated subjects [11]. Ideally this
approach also called “Systems Vaccinology” should help predict-
ing in early exploratory trials which adjuvants are more safe and
efﬁcacious and deserve to be advanced in larger, more expensive
phase II and III trials.
3. Beyond adjuvants
In addition to the use of adjuvants described above, there are
non-conventional ways to enhance immune responses to vaccina-
tion that may  represent a valid option for the future as described
by Raﬁ Ahmed [24] and by Raﬁck Sekaly [25]. Conventional adju-
vants for example have not been very successful in enhancing the
efﬁcacy of therapeutic vaccine to cure cancer or chronic infec-
tions, which are both known to induce immune-suppression of
T cell functions. The combination of adjuvanted vaccines and
monoclonal antibodies blocking inhibitory receptors such as pro-
grammed cell death-1 (PD-1) and cytotoxic T lymphocyte antigen-4
(CTLA4) may  be the right strategy for therapeutic interventions
against this type of diseases. Monoclonal antibodies targeting
CTLA4, PD-1, and PD1 ligand 1 have been very successfully used
for immunotherapy of several form of cancer including melanoma
[12–14]. Several reports have demonstrated that these antibodies
work by allowing the activation of the pre-existing natural cel-
lular immune responses to the tumor. In essence, those patients
with an immune system that has recognized the tumor producing
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umor-inﬁltrating immune cells are particularly sensitive to mono-
lonal antibodies targeting CTLA4 and PD1 pathways [15]. The co-
dministration of these monoclonal antibodies and vaccines based
n appropriate tumor associated antigens may  further increase
he number of responders to the therapy, in particular for the
atients that have weak natural immune responses to the tumor,
r for all those tumors that are not very immunogenic in general.
ytokines inducing T cell proliferation and differentiation, such as
L2, may  further enhance the efﬁcacy of therapeutic vaccines in
hronic conditions. Another strategy with the potential to enhance
herapeutic vaccine immunity is the depletion of regulatory
mmune cells like myeloid-derived suppressor cells and regulatory
 cells.
In addition to the combined immunotherapeutic strategies sum-
arized above, vaccine immunity may  be enhanced by combining
hem with inhibitors of metabolic pathways such as mTOR and
CN2. For instance it has been demonstrated that the mTOR
nhibitor rapamycin has a stimulatory effect in the generation of
emory CD8 responses [16].
New strategies to enhance vaccine efﬁcacy alternative to clas-
ical immunepotentiators may  arise also for preventive vaccines.
ystems vaccinology studies have shown that immune activa-
ion prior to vaccination negatively correlates with the response
o yellow fever 17D vaccine [17]. Therefore a potential strat-
gy to enhance the response to preventive vaccines may  be to
educe inﬂammation baseline before immunization by adminis-
ration of anti-inﬂammatory drugs. Finally, preclinical studies have
emonstrated that the gut microbioma inﬂuence the response to
nfection and vaccination. For example, it has been shown that
LR5-mediated sensing of gut microbiota is necessary for antibody
esponses to seasonal inﬂuenza vaccination in mouse [18]. If similar
echanisms exist also in human, in the future microbiome mod-
lators may  be exploited to enhance or modulate the response to
ral and even parenteral vaccines.
. Capturing the full value of vaccines
All the breakthrough technologies described above could help
eveloping novel vaccines able to prevent or cure an increasing
umber of communicable as well as non-communicable diseases.
owever, developing an effective vaccine is not enough; after
pproval the vaccine still needs to be implemented and accepted
y the public. Capturing the full value of vaccines is a critical
tep for achieving appropriate public health recommendations.
ecently, decisions regarding the introduction of new vaccines have
ncluded not only the impact on speciﬁc medical needs, but also
 health economic evaluation. David Bloom [26] has suggested
hat existing tools for health economic evaluation of vaccines suf-
er from an overly restricted approach that does not take into
ccount all the direct and indirect beneﬁts of vaccination. Tradi-
ional health economic approaches have assessed the reduction
f morbidity and mortality directly linked to prevention of dis-
ase by the vaccine, with the consequent healthcare savings and
ncreased individual productivity. A more comprehensive approach
hould include additional beneﬁts related to prevention of dis-
ases, such as improvement in education, mental health, increased
roductivity of the family that does not have to cure a sick mem-
er, reduced risk of contracting the disease in non-vaccinated
ndividuals (herd immunity), lower use of antibiotics and conse-
uent reduction in antimicrobial resistance and increased number
f tourists visiting the country. Recognizing all the beneﬁts of
accination, including indirect beneﬁts for the family or the com-
unity, it is a very important element to support recommendation
f new vaccines by public health and to increase acceptance. Impor-
antly, the Institute of Medicine developed a software system called
[
[3S (2015) B60–B63
SMART vaccines described here by Guruprasand Madhavan [27].
The SMART software can be used to rank vaccines based on a
list of 28 pre-deﬁned attributes and a list of 7 attributes deﬁned
by the users. This software will greatly facilitate strategic vaccine
prioritization efforts by industry and public health and, together
with other tools, can contribute to guide decision on vaccine rec-
ommendation based on a more comprehensive analysis of their
impact.
In summary, in order to capture the full potential of vaccines
multiple innovative approaches are needed in several ﬁelds: new
breakthrough technologies during vaccine discovery; innovative
clinical trial design during vaccine development; new tools to mea-
sure vaccine impact and innovative communication strategies to
improve acceptance by the public. The workshop “Enhancing vac-
cine Immunity and Value” has to be considered as a ﬁrst step to
improve alignment and communication among vaccine stakehol-
ders from different ﬁelds. More work from multidisciplinary teams
needs to be performed in order to maximize the impact of existing
and novel vaccines in the future.
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